Gilead lifted by $3.6B 1Q sales of newest hepatitis C pill



Estimated read time: 1-2 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

FOSTER CITY, Calif. (AP) — Gilead Sciences raked in $3.6 billion from sales of its newest hepatitis C pill, lifting the drugmaker's results past Wall Street expectations.

U.S. regulators approved the pill, Harvoni, in October and European Union regulators followed suit in November.

Meanwhile, sales of Gilead's previous hepatitis C drug, Sovaldi, dropped 57 percent to $972 million. It was approved in December 2013.

Harvoni and Sovaldi are both considered breakthrough treatments for the hepatitis C virus. But the Foster City, California-based company has been criticized over the high cost of the drugs. The U.S. list price for twelve weeks of treatment with Harvoni is $94,500.

Gilead Sciences Inc. said Thursday that its net income nearly doubled, and excluding one-time charges it reported a profit of $2.94 per share. Gilead's revenue surged 52 percent to $7.59 billion as revenue from Gilead's HIV drugs Truvada, Stribild and Complera and hepatitis B drug Viread all grew.

Analysts expected net income of $2.31 per share on $6.76 billion in revenue, according to a survey by Zacks Investment Research.

The company also declared its first dividend, saying it will pay 43 cents on June 29.

Shares of Gilead rose 1.8 percent to $102.28 in aftermarket trading.

The stock had closed down 1.8 percent, at $100.51, and is up almost 6 percent in 2015.

_____

Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on GILD at http://www.zacks.com/ap/GILD

_____

Keywords: Gilead Sciences, Earnings Report

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast